Search

Redo coronary artery bypass grafting (CABG) is associated with higher morbidity and mortality when compared to first-time CABG. Myocardial infarction and dysfunction contribute significantly to the increased risk of redo CABG. Results of reoperative coronary surgery have gradually improved, largely because of improvements in myocardial protection techniques. In the present review we will highlight the principles of myocardial protection in redo CABG patients with an emphasis on retrograde cardioplegia. [ABSTRACT FROM AUTHOR]

Cardiac cell therapies offer distinct and exciting advantages over current treatments to prevent postinfarction heart failure because they can reverse ventricular remodeling and improve function, but only if the implanted stem cells contribute biological functions and achieve prolonged engraftment within the hostile environment of the damaged heart. Unfortunately, function is diminished in autologous stem cells isolated from older patients and those with comorbidities, and so clinical trials testing the implantation of healthy, allogeneic bone marrow–derived stromal cells (MSCs) isolated from young donors are currently underway. MSCs are unique because, in addition to exerting paracrine effects that restore blood flow and recruit endogenous stem cells to the infarct, they exhibit immune-modulating properties in culture that—if retained after allogeneic implantation—imply the cells may escape immune recognition within the heart. At present, the scope of MSC immune modulation after implantation is unclear. (J Card Surg 2010;25:359-366) [ABSTRACT FROM AUTHOR]

Studies the potential beneficial effects of cerivastatin on temporary regional myocardial ischemia. Determination of whether cerivastatin has an effect on the area at risk and infarction after reperfusion; Employment of a temporary coronary artery occlusion model in rats; Ability of cerivastatin to increase myocardial tolerance to prolonged temporary ischemia.